Immune-Mediated Therapeutics for Cancer Portal AstraZeneca/MedImmune

MedImmune, the global biologics research and development arm of AstraZeneca, engaged 5AM Solutions to develop a portal to support R&D in their Immune-Mediated Therapeutics for Cancer (IMTC) program.

MedImmune has access to a variety of clinical and genomic data from both internal and external sources but often face arduous manual integration efforts before the data can be used. Biomarker discovery and hypothesis validation was being impacted negatively in terms of time, money and ability to collaborate and learn.

5AM designed and implemented a production solution for bringing together clinical and genomic data from disparate sources in different formats to support researchers to browse and analyze data from studies of interest to answer biological questions across many different cancer types, like:

  • What biomarkers for improved survival can we discover and confirm across studies?
  • What signatures can we confirm using multiple assay types to create a compelling biological story?
Survival graph for lung squamous cell carcinoma
Survival graph for lung squamous cell carcinoma